ABSTRACT
There is strong evidence for the putative role of the nucleus accumbens (NAc) in appetitive motivation. A first-in-human feasibility trial of responsive deep brain stimulation (rDBS) for loss of control eating provided a rare opportunity to examine the physiologic and structural underpinnings of NAc function in a human participant with dysregulated appetition. Patient-specific probabilistic tractography was supplemented by intraoperative microelectrode recordings and stimulation testing to confirm appetitive circuit engagement. Personalized visual stimuli we used to provoke and map appetitive units within the NAc, prior to the surgical implantation of a rDBS system, which was safe, feasible, and well-tolerated. Ambulatory patient-triggered recordings provide ongoing electrophysiologic surveillance of NAc activity time-locked to eating behavior in the real-world. This technique described provides a proof-of-concept for utilizing simultaneous intracranial activity and real-time appetitive responses to guide implantation of a rDBS system to treat loss of control eating.
Competing Interest Statement
No funding from NeuroPace was received for this study nor were data analyses reported here conducted by NeuroPace employees. C.H, R.S.S, and C.E.R have patents related to sensing and brain stimulation for the treatment of neuropsychiatric disorders. C.H. receives speaking honoraria from Boston Scientific. J.J.P, D.A.B, C.R, R.S.S, R.J, T.P, A.F, Y.H, B.K, and N.W declare no relevant financial disclosures or potential conflicts of interest outside of those enumerated above.
Clinical Trial
NCT03868670 (this manuscript describes a novel targeting and mapping technique and does not discuss prospective therapeutic outcomes of stimulation).
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03868670
Funding Statement
The study was funded by a NIH UH3 grant (NS103446)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A FDA IDE was sought and obtained for the initiation of a first in human clinical trial performed at Stanford Healthcare. The study protocol was reviewed and approved by a Stanford Institutional Review Board. https://clinicaltrials.gov/ct2/show/NCT03868670
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
